New combo targets tough breast cancer in early trial

NCT ID NCT05095207

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two drugs, abemaciclib and bicalutamide, together in people with a type of metastatic breast cancer that has spread and is positive for androgen receptors but negative for HER2. The goal is to find the safest dose and see if the combination can control the disease. About 42 adults are being enrolled in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib and bicalutamide
What this could lead to: If this works, it could offer a new treatment option for people with a specific type of metastatic breast cancer that is hard to treat.
What could go wrong: This is an early-phase trial with only 42 people, so it may not show enough benefit or could have side effects that limit its use. It is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer metastatic neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER METASTASIS

Contacts and locations

Locations

Dubin breast Center
RECRUITING

New York, New York, 10029, United States
Mount Sinai - West
RECRUITING

New York, New York, 10019, United States
Mount Sinai Beth Israel
RECRUITING

New York, New York, 10003, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.